U.S. health regulator pulls up Jagsonpal Pharmaceuticals for manufacturing lapses at API plant

The U.S. health regulator has issued a warning letter to Jagsonpal Pharmaceuticals for significant manufacturing lapses at its Rajasthan-based active pharmaceutical ingredients (APIs) plant. The U.S. Food and Drug Administration (USFDA) identified deviations from Current Good Manufacturing Practice for APIs during inspections on multiple dates in 2024. The company must address the deficiencies within 15 working days to prevent further regulatory action and ensure compliance with CGMP requirements.

Full Article